View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Suvoda WP
October 8, 2012updated 11 Jul 2022 9:58am

University of Texas unveil new lab designed to speed up pre-human clinical trials

A new lab has opened in the University of Texas that is designed to service a gap in the development of new drugs and biotechnology products.

By Heidi Vella

New clinic built

A new lab has opened in the University of Texas that is designed to service a gap in the development of new drugs and biotechnology products.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The lab was build for the purpose of rigorously testing the effectiveness and safety of new drugs as is required by the Food and Drug Administration, before drugs can be tested in a human clinical trial.

The facility, which is known as a Good Laboratory Practices (GLP) laboratory and provides assurances that procedures and documentation meet FDA standards, cost around $1 million to set up and is being funded by the university,

The University of Texas hope having a GLP will cut costs and time.

"These are the final, pivotal studies that the FDA will review before they are allowed into human trials," said executive director and chief technology officer of the university’s Drug Dynamics Institute, which overseas the lab, Janet Walkow.

The laboratory, named UT Advance, is at the Dell Pediatric Research Institute near the Dell Children’s Medical Center of Central Texas.

The university hopes the lab will also aid in the filing of patents and in reaching commercialisation agreements for pharmaceuticals and biomedical technology.

"We have outstanding preclinical research programs in drug development and targeted drug delivery," said dean of the College of Pharmacy, M. Lynn Crismon.

"The lab was build for the purpose of rigorously testing the effectiveness and safety of new drugs as is required by the Food and Drug Administration."

"This facility will help our researchers in these areas move more efficiently and effectively to get their discoveries into human trials."

The lab will be open for biotech companies and other entities outside the university.

University of Texas researchers are currently developing drugs to treat lung transplant patients and people suffering from cancer and viruses such as influenza and other diseases.

The first drug planned to be tested at the facility is inhaled immune suppressing drug capable of treating patients who have had a lung transplant.


Caption: University of Texas researchers are currently developing drugs to treat lung transplant patients. Credit: Kurhan.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology